{"filing":{"accession_number":"0001410098-26-000040","cik":"0001410098","ticker":"CRMD","company_name":"CorMedix Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"crmd-20260629.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1410098/000141009826000040/crmd-20260629.htm"},"events":[{"id":15908,"run_id":14187,"accession_number":"0001410098-26-000040","anchor_item_number":"8.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The disclosure centers on the Board's appointment of Elizabeth Hurlburt to a newly created role of Chief Operating and Commercial Officer with expanded functional oversight of commercial functions, medical affairs, regulatory and clinical. While Michael Seckler's departure is mentioned, the principal action disclosed is Hurlburt's appointment to an expanded executive position. The expansion of her role and new title constitute a material change in executive leadership structure.","company_name":"CorMedix Inc.","ticker":"CRMD","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13829,"accession_number":"0001410098-26-000040","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on the Board's appointment of Elizabeth Hurlburt to a newly created role of Chief Operating and Commercial Officer with expanded functional oversight of commercial functions, medical affairs, regulatory and clinical. While Michael Seckler's departure is mentioned, the principal action disclosed is Hurlburt's appointment to an expanded executive position. The expansion of her role and new title constitute a material change in executive leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:34:59.347344+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13829,"accession_number":"0001410098-26-000040","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on the Board's appointment of Elizabeth Hurlburt to a newly created role of Chief Operating and Commercial Officer with expanded functional oversight of commercial functions, medical affairs, regulatory and clinical. While Michael Seckler's departure is mentioned, the principal action disclosed is Hurlburt's appointment to an expanded executive position. The expansion of her role and new title constitute a material change in executive leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:34:59.347344+00:00","company_name":"CorMedix Inc.","ticker":"CRMD","filing_date":"2026-07-02"}]}